These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21897115)

  • 1. Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry.
    Wildemberg LE; Vieira Neto L; Costa DF; Nasciutti LE; Takiya CM; Alves LM; Gadelha MR
    J Endocrinol Invest; 2012 Jun; 35(6):580-4. PubMed ID: 21897115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
    Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
    PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs.
    Wildemberg LE; Neto LV; Costa DF; Nasciuti LE; Takiya CM; Alves LM; Rebora A; Minuto F; Ferone D; Gadelha MR
    J Endocrinol Invest; 2013 Jan; 36(1):38-43. PubMed ID: 22472799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
    Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
    J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
    Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
    Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
    Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
    Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly.
    Venegas-Moreno E; Vazquez-Borrego MC; Dios E; Gros-Herguido N; Flores-Martinez A; Rivero-Cortés E; Madrazo-Atutxa A; Japón MA; Luque RM; Castaño JP; Cano DA; Soto-Moreno A
    J Cell Mol Med; 2018 Mar; 22(3):1640-1649. PubMed ID: 29266696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.
    Fan X; Mao Z; He D; Liao C; Jiang X; Lei N; Hu B; Wang X; Li Z; Lin Y; Gou X; Zhu Y; Wang H
    J Endocrinol Invest; 2015 Oct; 38(10):1117-28. PubMed ID: 26036598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
    Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
    Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
    Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells.
    Mariniello B; Finco I; Sartorato P; Patalano A; Iacobone M; Guzzardo V; Fassina A; Mantero F
    J Endocrinol Invest; 2011 Jun; 34(6):e131-8. PubMed ID: 21042045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
    Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
    Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
    Rass L; Rahvar AH; Matschke J; Saeger W; Renné T; Aberle J; Flitsch J; Rotermund R
    Hormones (Athens); 2022 Mar; 21(1):79-89. PubMed ID: 34674191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Transforming Growth Factor β1, Smad3, and Phospho-Smad3 in Somatotropinomas and Their Relationship to Tumor Behavior.
    Li Z; Li J; Shan X; Gui S; Li C; Zhang Y
    World Neurosurg; 2021 Sep; 153():e20-e27. PubMed ID: 34087455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide.
    Gonzalez B; Vargas G; Ramirez C; Asa S; Cheng S; Sandoval C; Mercado M
    Endocrinol Nutr; 2014 Dec; 61(10):523-30. PubMed ID: 25008035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide.
    Takei M; Suzuki M; Kajiya H; Ishii Y; Tahara S; Miyakoshi T; Egashira N; Takekoshi S; Sanno N; Teramoto A; Osamura RY
    Endocr Pathol; 2007; 18(4):208-16. PubMed ID: 17987403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
    Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
    Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression.
    Corbetta S; Ballaré E; Mantovani G; Lania A; Losa M; Di Blasio AM; Spada A
    Eur J Clin Invest; 2001 Mar; 31(3):208-14. PubMed ID: 11264647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors.
    Panetta R; Patel YC
    Life Sci; 1995; 56(5):333-42. PubMed ID: 7530798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.